Baxdrostat Evidence: Trial Results and Peer-Reviewed Publications

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

1. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24.
   Flack JM, Azizi M, Brown JM, et al. · Hypertens Res · 2025
   PubMed: PMID 40850955 · NCT06034743 (BaxHTN) · Hypertension
2. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension.
   Flack JM, Azizi M, Brown JM, et al. · N Engl J Med · 2025
   PubMed: PMID 40888730 · NCT06034743 (BaxHTN) · Hypertension
3. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial.
   Dwyer JP, Maklad N, Vedin O, et al. · J Am Soc Nephrol · 2026
   PubMed: PMID 40913594 · NCT06677060 (Prevent-HF) · Heart Failure
4. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
   Azizi M, Brown JM, Dwyer JP, et al. · Lancet · 2026
   PubMed: PMID 41794437 · NCT06168409 (Bax24) · Hypertension

Publications by year

2025–2026: 4 publications.

Publications by indication

Publications by journal

• Hypertens Res1 paper
• N Engl J Med1 paper
• J Am Soc Nephrol1 paper
• Lancet1 paper

All Baxdrostat publications (4)

Sources and methodology

• Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
• Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
• Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
• Data freshness: Thu, 07 May 2026 20:08:26 GMT.